Last reviewed · How we verify
A Phase II, Dose Ranging Multi-Centre, Single Blind, Parallel-Group, Controlled Study of the Safety, Tolerability and Immunogenicity of Recombinant (rPA Based) Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed in a Healthy Population
This is a dose ranging study comparing different vaccine schedules of rPA vaccine, for Anthrax, to the licensed dose of AVA, another Anthrax vaccine. Safety and the capability to induce an immune response will be evaluated.
Details
| Lead sponsor | PharmAthene UK Limited |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 226 |
| Start date | 2005-03 |
| Completion | 2007-02 |
Conditions
- Bacillus Anthracis (Anthrax)
Interventions
- AVA
- rPA vaccine containing alhydrogel
Primary outcomes
- Safety of rPA vaccine
Countries
United States